Global Vaccine Partnering Terms and Agreements Dir

Dublin, May 22, 2018 (GLOBE NEWSWIRE) -- The "Global Vaccine Partnering Terms and Agreements 2010-2018: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering. The Global Vaccine Partnering Terms and Agreements 2010-2018: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the vaccine partnering deals and agreements entered into by the worlds leading healthcare companies. One of the key highlights of the report is that over 1,000 online deals records of actual vaccine deals as disclosed by the deal parties are included towards the end of the report in a directory format that is easy to reference. Each deal links via Weblink to an online version and all these deals are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy and technology focus. In addition the report includes actual contract documents where available as submitted to the Securities Exchange Commission by companies and their deal partners. The report takes readers through the vaccine deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering vaccine partnering deals. The report presents average financial deal terms values for vaccine deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals. Global Vaccine Partnering Terms and Agreements 2010-2018

• Trends in vaccine dealmaking in the biopharma industry since 2010
• Analysis of vaccine deal structure
• Access to headline, upfront, milestone and royalty data
• Case studies of real-life vaccine deals
• Access to over 1,000 vaccine deal documents
• The leading vaccine deals by value since 2010
• Most active vaccine dealmakers since 2010
• The leading vaccine partnering resources

Available contracts are listed by:

• Company A-Z
• Headline value
• Stage of development at signing
• Deal component type
• Therapy target
• Specific technology type

Key Topics Covered: Executive Summary Chapter 1 - Introduction Chapter 2 - Trends in Vaccines dealmaking 2.1. Introduction 2.2. Vaccines partnering over the years 2.3. Most active Vaccines dealmakers 2.4. Vaccines partnering by deal type 2.5. Vaccines partnering by therapy area 2.6. Deal terms for Vaccines partnering 2.6.1 Vaccines partnering headline values 2.6.2 Vaccines deal upfront payments 2.6.3 Vaccines deal milestone payments 2.6.4 Vaccines royalty rates Chapter 3 - Leading Vaccines deals 3.1. Introduction 3.2. Top Vaccines deals by value Chapter 4 - Most active Vaccines dealmakers 4.1. Introduction 4.2. Most active Vaccines dealmakers 4.3. Most active Vaccines partnering company profiles Chapter 5 - Vaccines contracts dealmaking directory 5.1. Introduction 5.2. Vaccines contracts dealmaking directory Chapter 6 - Vaccines dealmaking by technology type Chapter 7 - Partnering resource center 7.1. Online partnering 7.2. Partnering events 7.3. Further reading on dealmaking Appendices Appendix 1 - Vaccines deals by company A-Z Appendix 2 - Vaccines deals by stage of development Discovery Preclinical Phase I Phase II Phase III Regulatory Marketed Formulation Appendix 3 - Vaccines deals by deal type Asset purchase Assignment Bigpharma outlicensing Co-development Collaborative R&D Co-market Co-promotion CRADA Cross-licensing Development Distribution Equity purchase Evaluation Grant Joint venture Licensing Manufacturing Marketing Material transfer Option Promotion Research Settlement Spin out Sub-license Supply Technology transfer Termination Appendix 4 - Vaccines deals by therapy area Anaesthetics Cardiovascular Central Nervous System Dental Gastrointestinal Hematology Immunology Infectives Metabolic Musculoskeletal Oncology Ophthalmics Orphan disease Pediatrics Psychiatry Respiratory Appendix 5 - Deal type definitions For more information about this report visit https://www.researchandmarkets.com/research/g...ccine?w=12

CONTACT: ResearchAndMarkets.com Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Vaccines